May 19, 2026 - ChartAlert®

BEL – Bharat Electronics – Q4 FY26 Financial Results – 19-May-26

BEL/ Bharat Electronics’ FY26 delivered 16.2% revenue and 13.9% PAT growth with debt‑free balance sheet and improving OCF, confirming defence capex cycle strength. Risks: 43 bps margin compression, opex outpacing revenue, thin ~9% FCF, and ₹12,87,576L receivables. FY27 re‑rating hinges on receivable resolution and WC signals.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.2% YoY (₹23,76,875L → ₹27,61,011L), with Q4FY26 alone at ₹10,22,443L — a 11.8% beat over Q4FY25’s ₹9,14,959L, confirming back-half loading.
Sequential Q4 surge (₹7,15,385L in Q3 → ₹10,22,443L) reflects typical defence order execution bunching in year-end quarter.
Other income declined sharply YoY (₹74,236L → ₹56,603L), pulling total income growth slightly below revenue growth at 14.9%.

Bottomline

Net profit grew 13.9% YoY (₹5,32,268L → ₹6,06,226L); Q4FY26 PAT of ₹2,22,635L surpassed Q4FY25’s ₹2,12,702L by 4.7%.
Effective tax rate eased to 25.2% vs 25.5% in FY25, aided by deferred tax credit of ₹3,491L (vs ₹4,150L charge in FY25) — meaningful swing.
EPS rose from ₹7.28 to ₹8.29 (+13.9%), fully diluted, on unchanged share capital.

Margins

EBIT (PBT ex-other income, ex-finance cost): ₹27,61,011L revenue vs PBT ₹8,05,296L less other income ₹56,603L plus finance cost ₹673L = operating profit ₹7,49,366L → EBIT margin ~27.1% vs prior year: ₹7,09,900L – ₹74,236L + ₹968L = ₹6,36,632L on ₹23,76,875L → 26.8%. Marginal expansion of ~30 bps.
Net profit margin: ₹6,06,226L ÷ ₹27,61,011L = 21.96% vs ₹5,32,268L ÷ ₹23,76,875L = 22.39% — slight 43 bps compression, driven by faster opex growth.
Employee costs grew faster than revenue (12.9% → ₹3,11,555L); other expenses jumped 21.4% (₹1,98,719L → ₹2,41,208L), indicating cost base expanding ahead of topline.

Growth Trajectory

16.2% revenue CAGR (1-year) on a large base signals continued defence capex tailwinds; order book execution is accelerating.
PAT growth lagging revenue growth (13.9% vs 16.2%) — margin dilution risk if opex inflation persists.
Q4 concentration (~37% of FY revenue) remains a structural feature; execution risk is high if year-end order flows are delayed.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

Zydus’ FY26 shows EBITDA margin expansion and Pharma EBIT at multi‑year highs, but acquisitions flipped net cash to net debt, collapsed OCF, and added loss‑making Med Tech and Consumer units. FY27 re‑rating hinges on OCF recovery, debt reduction, and margin inflection in new segments.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.8% YoY (₹232,415 Mn → ₹271,484 Mn), led by Pharma (₹205,415 Mn → ₹224,121 Mn, +9.1%) and a near-doubling of Consumer Products (₹26,976 Mn → ₹39,540 Mn, +46.6%).
Medical Technologies contributed ₹7,823 Mn in FY26 vs ₹24 Mn in FY25 — full-year impact of an acquired business.
Q4FY26 revenue of ₹75,870 Mn was up 16.2% YoY vs Q4FY25 (₹65,279 Mn), with sequential improvement from Q3FY26 (₹68,645 Mn).

Bottomline

Net profit grew 11.3% YoY (₹45,255 Mn → ₹50,400 Mn); exceptional items of ₹5,166 Mn (vs ₹2,196 Mn in FY25) weighed on reported PAT.
Pre-exceptional PBT rose 14.3% YoY (₹62,463 Mn → ₹71,377 Mn) — underlying earnings quality remains strong.
Effective tax rate dropped meaningfully: 23.4% in FY26 vs 23.4% in FY25 — stable, no distortion from deferred tax movements at the net level.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): ₹71,377 + ₹14,080 + ₹4,389 = ₹89,846 Mn on revenue of ₹271,484 Mn → EBITDA margin ~33.1% vs ₹62,463 + ₹9,158 + ₹1,699 = ₹73,320 Mn on ₹232,415 Mn → 31.5% in FY25. ~160 bps expansion YoY.
Net profit margin: ₹50,400 / ₹271,484 = 18.6% vs ₹45,255 / ₹232,415 = 19.5% — 90 bps compression, driven by higher D&A (₹14,080 Mn vs ₹9,158 Mn) and finance costs (₹4,389 Mn vs ₹1,699 Mn) post-acquisitions.
Consumer Products EBIT margin compressed sharply: ₹2,671 / ₹39,540 = 6.8% vs ₹3,470 / ₹26,976 = 12.9% — the acquired business is dilutive at EBIT level.

Growth Trajectory

3-year revenue compounding is intact; FY26’s 16.8% growth is above-industry for a company of this scale.
Pharma segment — the core engine — delivered only 9.1% growth; incremental revenue acceleration depended heavily on acquisitions.
Medical Technologies segment is loss-making (EBIT: -₹1,782 Mn) and rapidly scaling costs — trajectory unclear without further disclosure.

SOLARINDS – Solar Industries India – Q4 FY26 Earnings Call – 15-May-26

Solar Industries’topline growth is defense/international-led, margins hinge on commodity pass-through and mix, and bottomline resilience depends on subsidiary execution and working capital normalization.

1–2 minutes

Also see: SOLARINDS – Solar Industries India – Q4 FY26 Financial Results – 15-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Defense hits INR4,500 crores, international grows 25%, and domestic recovers modestly. Commodity lag pressures Q1 margins, but full-year EBITDA holds at 27–28%. Revenue: INR14,000 crores, EPS growth: 10–12%.

TMCV – Tata Motors Limited – Q4 FY26 Earnings Call – 13-May-26

Tata Motors’ topline resilience hinges on diesel/commodity stability and international execution; margins depend on cost discipline and pricing power; FCF remains robust under disciplined capital allocation.

1–2 minutes

Also see: TMCV – Tata Motors Limited (Formerly TML Commercial Vehicles Limited) – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Diesel prices stabilize; commodity inflation moderates in H2 FY27. Single-digit volume growth in Q1 FY27 sustains, with teens EBITDA margins via cost discipline and selective price hikes. Indonesia order deliveries ramp, offsetting MENA/SAARC softness. FCF at 10–12% of revenue; net cash position stable. Iveco deal closes in Q2 FY27, adding strategic depth.

DLF – DLF Limited – Q4 FY26 Earnings Call – 13-May-26

DLF’s base case supports 10–12% topline growth, 15% bottomline expansion, and stable margins, with upside tied to Dahlias and rental NOI, and downside to execution delays and SEZ vacancies.

1–2 minutes

Also see: DLF – DLF Limited – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

FY27 sales hit INR 20,000 crore (Dahlias: INR 5,500 crore; launches: INR 13,500 crore). Rental NOI grows 15% CAGR (INR 8,200 crore exit run-rate). RERA escrow unlocks INR 5,000 crore in FY27, funding dividends (INR 8–9/share) and capex. Topline: +10–12% YoY; Bottomline: +15% (DCCDL-led); Margins: Stable at 39–40%.

MTARTECH – MTAR Technologies – Q4 FY26 Earnings Call – 12-May-26

MTAR Technologies’ topline growth is order-book-driven, but margins and cash flow hinge on working capital management and capex execution efficiency.

1–2 minutes

Also see: MTARTECH – MTAR Technologies – Q4 FY26 Financial Results – 12-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Order book supports 15-20% revenue growth, but margin expansion capped at 19-20% due to material costs. Working capital remains elevated (receivables 130-140 days), and PAT grows 15-20% YoY with controlled capex execution.

DRREDDY – Dr. Reddy’s Laboratories – Q4 FY26 Earnings Call – 12-May-26

Dr. Reddy’s Laboratories’ topline growth hinges on semaglutide/abatacept execution, bottomline resilience depends on margin recovery via mix shift, and margins face structural pressure without high-margin scale.

1–2 minutes

Also see: DRREDDY – Dr. Reddy’s Laboratories – Q4 FY26 Financial Results – 12-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Semaglutide 10–11M units in FY27 (Brazil delay to FY28) + abatacept launch late CY27. Gross margin ~50%, EBITDA margin ~23–24% as price erosion and SSA drag persist. North America stabilizes but biosimilars scale slowly; FY29 biosimilars sales ~US$500M. EPS growth flat without margin expansion.

SYRMA – Syrma SGS Technology – Q4 FY26 Earnings Call – 11-May-26

Syrma SGS Technology’s topline growth of 30–35% is achievable with margin compression to 10–10.5% due to structural cost pressures, offset by ODM/export mix improvements and operating leverage.

1–2 minutes

Also see: SYRMA – Syrma SGS Technology – Q4 FY26 Financial Results – 11-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Geopolitical tensions persist, but cost pass-throughs partially offset inflation. PCB capex proceeds as planned, with subsidies in FY’29. Exports grow 25%, and ODM sustains at 17%. Revenue: INR 6,200–6,400 crores; EBITDA: INR 700–720 crores (10.5–11% margin).

OBEROIRLTY – Oberoi Realty – Q4 FY26 Earnings Call – 11-May-26

Oberoi Realty’s topline growth hinges on launch execution and luxury absorption, while margins and cash flows are most sensitive to cost inflation and RLDA financing choices.

1–2 minutes

Also see: OBEROIRLTY – Oberoi Realty – Q4 FY26 Financial Results – 8-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Launches proceed on schedule, but Gurgaon absorption lags at 50% in Year 1. RLDA 50% strata sale offsets discount rate drag. 2–3% cost inflation fully absorbed by contingencies. FY27 revenue grows 10–12%, with margins stable but OCF pressured by land payments. Unrecognized revenue delays 5–10% of FY27 revenue to FY28.

AMBUJACEM – Ambuja Cements – Q4 FY26 Earnings Call – 4-May-26

Ambuja Cements’ topline growth hinges on volume execution (80M tonnes target), bottomline resilience depends on INR250/tonne cost savings, and margins are at risk if pricing power remains weak.

1–2 minutes

Also see: AMBUJACEM – Ambuja Cements – Q4 FY26 Financial Results – 4-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Demand grows 5–5.5% (industry) with Ambuja at 8% volume growth (80M tonnes). INR250/tonne cost savings achieved via fly ash/green energy, offsetting INR50–100/tonne inflation. EBITDA/tonne stabilizes at INR850–900 (from INR887 in FY26). Capex at INR6,000–6,500 crore supports gradual capacity additions. Margins flat to slightly down due to pricing constraints.